ALK-driven tumors and targeted therapy: focus on crizotinib
Citations Over TimeTop 10% of 2014 papers
Abstract
Receptor tyrosine kinases have emerged as promising therapeutic targets for a diverse set of tumors. Overactivation of the tyrosine kinase anaplastic lymphoma kinase (ALK) has been reported in several types of malignancies such as anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, and non-small-cell lung carcinoma. Further characterization of the molecular role of ALK has revealed an oncogenic signaling signature that results in tumor dependence on ALK. ALK-positive tumors display a different behavior than their ALK-negative counterparts; however, the specific role of ALK in some of these tumors remains to be elucidated. Although more studies are required to establish selective targeting of ALK as a definitive therapeutic option, initial trials have shown extraordinary results in the majority of cases.
Related Papers
- → The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma(2012)322 cited
- → Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma(2012)31 cited
- → The anaplastic lymphoma kinase as an oncogene in solid tumors(2015)5 cited
- → Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer(2021)4 cited
- → Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma(2021)28 cited